Abstract
Solid tumors contain several different types of malignant cells. This cellular heterogeneity complicates therapy for at least two reasons. First, each subpopulation may respond differently to a given treatment. Second, cancer cells are plastic, and thus may convert from a therapy-sensitive to a therapy-resistant cell type represented by another subpopulation. Therefore, successful therapies will have to target numerous malignant cell types, not just the rapidly proliferating cells as most standard treatments do. Immunotherapies with T cells engineered to recognize cancer cells via bispecific antibodies (bsAbs) or chimeric antigen receptors (CARs) are particularly promising approaches with potential to ablate both dividing and non/slow-dividing subpopulations of cancer cells. Here, we discuss several patents associated with exceptionally effective bsAbs of the tandem single-chain variable fragment (taFv) class and untangle a part of the complex network of patents directly or indirectly related to CARs. Furthermore, we speculate on the future of bsAbs and CARs for both treatment and prevention of solid tumors such as prostate cancer.
Keywords: Antibody, BiTE, bispecific, cancer, CAR, scFv, taFv.
Recent Patents on Anti-Cancer Drug Discovery
Title:Cancer T Cell Immunotherapy with Bispecific Antibodies and Chimeric Antigen Receptors
Volume: 8 Issue: 3
Author(s): Markus D. Lacher and Maurizio Provenzano
Affiliation:
Keywords: Antibody, BiTE, bispecific, cancer, CAR, scFv, taFv.
Abstract: Solid tumors contain several different types of malignant cells. This cellular heterogeneity complicates therapy for at least two reasons. First, each subpopulation may respond differently to a given treatment. Second, cancer cells are plastic, and thus may convert from a therapy-sensitive to a therapy-resistant cell type represented by another subpopulation. Therefore, successful therapies will have to target numerous malignant cell types, not just the rapidly proliferating cells as most standard treatments do. Immunotherapies with T cells engineered to recognize cancer cells via bispecific antibodies (bsAbs) or chimeric antigen receptors (CARs) are particularly promising approaches with potential to ablate both dividing and non/slow-dividing subpopulations of cancer cells. Here, we discuss several patents associated with exceptionally effective bsAbs of the tandem single-chain variable fragment (taFv) class and untangle a part of the complex network of patents directly or indirectly related to CARs. Furthermore, we speculate on the future of bsAbs and CARs for both treatment and prevention of solid tumors such as prostate cancer.
Export Options
About this article
Cite this article as:
Lacher D. Markus and Provenzano Maurizio, Cancer T Cell Immunotherapy with Bispecific Antibodies and Chimeric Antigen Receptors, Recent Patents on Anti-Cancer Drug Discovery 2013; 8 (3) . https://dx.doi.org/10.2174/15748928113088880003
DOI https://dx.doi.org/10.2174/15748928113088880003 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bioengineered 3D Scaffolds in Cancer Research: Focus on Epithelial to Mesenchymal Transition and Drug Screening
Current Pharmaceutical Design Targeting Telomerase for Cancer Therapy
Current Cancer Therapy Reviews Nanoparticles for Tumor Targeted Therapies and Their Pharmacokinetics
Current Drug Metabolism Extraction, Isolation and Analysis of Chondroitin Sulfate Glycosaminoglycans
Recent Patents on Food, Nutrition & Agriculture Aspirin: A Potential Therapeutic Approach in Pancreatic Cancer
Current Medicinal Chemistry Statins-Mediated Inhibition of Rho GTPases as a Potential Tool in Anti-Tumor Therapy
Mini-Reviews in Medicinal Chemistry Telomere Maintenance as Therapeutic Target in Embryonal Tumours
Anti-Cancer Agents in Medicinal Chemistry In Silico Modeling of Crabtree Effect
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacological Perspectives of Wasp Venom
Protein & Peptide Letters Silver Nanoparticles with High Loading Capacity of Amphotericin B: Characterization, Bactericidal and Antifungal Effects
Current Drug Delivery Gene Expression-Based Pharmacodynamic Biomarkers: The Beginning of a New Era in Biomarker-Driven Anti-Tumor Drug Development
Current Molecular Medicine Bugs and Drugs: Oncolytic Virotherapy in Combination with Chemotherapy
Current Pharmaceutical Biotechnology Anticancer Vitamin K3 Analogs: A Review
Anti-Cancer Agents in Medicinal Chemistry Ketogenic Diet Acts on Body Remodeling and MicroRNAs Expression Profile
MicroRNA MicroRNA-7 Regulates Insulin Signaling Pathway by Targeting IRS1, IRS2, and RAF1 Genes in Gestational Diabetes Mellitus
MicroRNA Natural and Synthetic Naphthoquinones Active Against Trypanosoma Cruzi: An Initial Step Towards New Drugs for Chagas Disease
Current Medicinal Chemistry Molecular Treatment of Different Breast Cancers
Anti-Cancer Agents in Medicinal Chemistry Obesity and Metabolic Syndrome Affect the Cholinergic Transmission a nd Cognitive Functions
CNS & Neurological Disorders - Drug Targets Synthesis and Anti-thyroid Cancer Effect of Iodo-chrysin Derivatives
Medicinal Chemistry Recent Patents Related to Phosphorylation Signaling Pathway on Cancer
Recent Patents on DNA & Gene Sequences